Volume | 1,196,284 |
|
|||||
News | (1) | ||||||
Day High | 134.465 | Low High |
|||||
Day Low | 131.16 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sarepta Therapeutics Inc New | SRPT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
132.55 | 131.16 | 134.465 | 133.66 | 130.63 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
19,230 | 1,196,284 | $ 133.13 | $ 159,261,720 | - | 55.25 - 159.89 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:54:18 | 1 | $ 131.00 | USD |
Sarepta Therapeutics (SRPT) Options Flow Summary
Sarepta Therapeutics Inc New Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
12.54B | 93.86M | - | 1.24B | -535.98M | -5.71 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sarepta Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SRPT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 127.53 | 142.79 | 125.62 | 129.42 | 1,356,348 | 6.13 | 4.81% |
1 Month | 125.43 | 142.79 | 114.37 | 124.85 | 875,696 | 8.23 | 6.56% |
3 Months | 128.00 | 143.00 | 114.37 | 126.93 | 886,614 | 5.66 | 4.42% |
6 Months | 78.42 | 143.00 | 75.85 | 109.08 | 1,106,442 | 55.24 | 70.44% |
1 Year | 120.45 | 159.89 | 55.25 | 110.54 | 1,261,900 | 13.21 | 10.97% |
3 Years | 71.41 | 159.89 | 55.25 | 102.66 | 1,113,909 | 62.25 | 87.17% |
5 Years | 117.17 | 181.83 | 55.25 | 107.62 | 1,133,083 | 16.49 | 14.07% |
Sarepta Therapeutics Description
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. |